相关实验视频

Updated: Jul 16, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

顺序性静脉注射吉姆替宾/多塞塔克塞尔在BCG治疗后的高风险NMIBC中提供了持久的缓解

Kendrick Yim¹, Kevin Melnick¹, Sarah L Mott²

¹Division of Urology, Brigham and Women's Hospital, Boston, MA.

Urologic oncology

|September 10, 2023

概括

序列性静脉注射格美西塔/多塞塔为Bacillus Calmette-Guerin无反应性非肌肉侵入性膀癌提供了安全有效的治疗方法. 患有BCG复发性疾病的患者对这种疗法反应更好.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科

背景情况:

卡尔梅特-格林菌 (BCG) 是高风险非肌肉侵入性膀癌 (NMIBC) 的标准治疗方法.
一半接受BCG治疗的患者经历疾病复发,BCG不响应NMIBC的选择有限.

研究的目的:

评估BCG不响应NMIBC的患者的顺序性静脉注射凝胺/docetaxel (gem/doce) 的安全性,疗效和差异性反应.
基于BCG失败分类 (耐火性与复发性) 的结果进行比较.

主要方法:

对102名BCG不响应的NMIBC患者进行了回顾性分析,这些患者接受了静脉内静脉内静脉内静脉治疗.
使用卡普兰-梅尔曲线和考克斯回归的高度无复发生存率的评估.
记录了不良事件和治疗结果.

主要成果:

六,十二,二十四个月的高度无复发性生存率分别为78%,65%和49%.
大多数患者经历了轻度至中度的不良反应,治疗延迟很少.
与BCG复发性疾病患者相比,BCG耐药性疾病患者的高度复发可能性更高 (HR 2.14).

结论:

序列性静脉内结石/doce是BCG不响应的NMIBC的激进囊切除术的有效和耐受的替代方案.
患有BCG复发性疾病的患者对宝石/剂量疗法表现出更有利的反应.
需要进行前性试验,以进一步验证这些发现.

关键词:

在BCG中,BCG是BCG.膀癌是一种癌症.静脉内疗法是一种静脉内疗法.非肌肉侵入性膀癌是一种非肌肉侵袭性膀癌.结果的结果.

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.